Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Amneal Pharmaceuticals Inc Class A (AMRX) stocks

Learn how to easily invest in Amneal Pharmaceuticals Inc Class A stocks.

Amneal Pharmaceuticals Inc Class A is a drug manufacturers-specialty & generic business based in the US. Amneal Pharmaceuticals Inc Class A stocks (AMRX.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $4.69 – an increase of 7.44% over the previous week. Amneal Pharmaceuticals Inc Class A employs 7,000 staff and has a trailing 12-month revenue of around $2.1 billion.

How to buy stocks in Amneal Pharmaceuticals Inc Class A

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AMRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Amneal Pharmaceuticals Inc Class A stock price (NYSE:AMRX)

Use our graph to track the performance of AMRX stocks over time.

Amneal Pharmaceuticals Inc Class A shares at a glance

Information last updated 2022-06-25.
Latest market close$3.32
52-week range$2.90 - $5.99
50-day moving average $3.54
200-day moving average $4.44
Wall St. target price$6.42
PE ratio 266.6667
Dividend yield $0 (0%)
Earnings per share (TTM) $0.01

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99–$9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Amneal Pharmaceuticals Inc Class A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Amneal Pharmaceuticals Inc Class A price performance over time

Historical closes compared with the close of $3.32 from 2022-06-28

1 week (2022-06-22) 7.44%
1 month (2022-05-25) N/A
3 months (2022-03-29) -21.33%
6 months (2021-12-25) N/A
1 year (2021-06-29) -35.53%
2 years (2020-06-29) -28.91%
3 years (2019-06-28) 7.17
5 years (2017-06-29) 16.15

Is Amneal Pharmaceuticals Inc Class A under- or over-valued?

Valuing Amneal Pharmaceuticals Inc Class A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amneal Pharmaceuticals Inc Class A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amneal Pharmaceuticals Inc Class A's P/E ratio

Amneal Pharmaceuticals Inc Class A's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 267x. In other words, Amneal Pharmaceuticals Inc Class A shares trade at around 267x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Amneal Pharmaceuticals Inc Class A's EBITDA

Amneal Pharmaceuticals Inc Class A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $425.5 million.

The EBITDA is a measure of a Amneal Pharmaceuticals Inc Class A's overall financial performance and is widely used to measure a its profitability.

Amneal Pharmaceuticals Inc Class A financials

Revenue TTM $2.1 billion
Operating margin TTM 9.05%
Gross profit TTM $783.9 million
Return on assets TTM 3.02%
Return on equity TTM -0.21%
Profit margin 0.08%
Book value $2.59
Market capitalisation $969.4 million

TTM: trailing 12 months

Amneal Pharmaceuticals Inc Class A share dividends

We're not expecting Amneal Pharmaceuticals Inc Class A to pay a dividend over the next 12 months.

Amneal Pharmaceuticals Inc Class A share price volatility

Over the last 12 months, Amneal Pharmaceuticals Inc Class A's shares have ranged in value from as little as $2.9 up to $5.99. A popular way to gauge a stock's volatility is its "beta".

AMRX.US volatility(beta: 1.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Amneal Pharmaceuticals Inc Class A's is 1.1959. This would suggest that Amneal Pharmaceuticals Inc Class A's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Amneal Pharmaceuticals Inc Class A overview

Amneal Pharmaceuticals, Inc. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site